AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1858699 — intervention group
Group type: EXPERIMENTAL
Intervention: High linoleic acid diet (11.5% of energy)
Number of subjects: 7
Study 1858699 — intervention group
Group type: COMPARATOR
Intervention: Low linoleic acid diet (4.5% of energy)
Number of subjects: 7
Study 31600804 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural
Number of subjects: 65
Study 31600804 — intervention group
Group type: COMPARATOR
Intervention: PCA
Number of subjects: 65
Study 31045947 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive drugs (i.e. bisphosphonates)
Number of subjects: 0
Study 31045947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone anabolic drugs (i.e. teriparatide)
Number of subjects: 0
Study 31045947 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 31045947 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 0
Study 28541802 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment for co-occurring PTSD and substance use disorder
Number of subjects: 15
Study 24945268 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream
Number of subjects: 255
Study 24945268 — intervention group
Group type: COMPARATOR
Intervention: Moisturizing cream
Number of subjects: 255
Study 23474995 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training for 20 weeks
Number of subjects: 30
Study 23474995 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 21457842 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5° buccal root torque
Number of subjects: 15
Study 21457842 — intervention group
Group type: EXPERIMENTAL
Intervention: 15° buccal root torque
Number of subjects: 15
Study 19021095 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 0
Study 19021095 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 0
Study 17213476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg for 21 days)
Number of subjects: 14
Study 17213476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15502736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stroke
Number of subjects: 80
Study 11776423 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Structuring Intervention (MSI)
Number of subjects: 17
Study 11776423 — intervention group
Group type: COMPARATOR
Intervention: Supportive-listening control sessions
Number of subjects: 17
Study 9187784 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 9 micrograms.kg‐1
Number of subjects: 6
Study 9187784 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms.kg‐1
Number of subjects: 6
Study 9187784 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 6 micrograms.kg‐1
Number of subjects: 6
Study 9187784 — intervention group
Group type: COMPARATOR
Intervention: Control (0 micrograms.kg‐1)
Number of subjects: 6
Study 7943597 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hepatic perfusion chemotherapy via hepatic artery and portal vein with 5-fluorouracil (125 mg/d) for 28 to 35 days
Number of subjects: 20
Study 7943597 — intervention group
Group type: COMPARATOR
Intervention: Historical control groups
Number of subjects: 20
Study 2835743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined measles, mumps, rubella, and varicella vaccine
Number of subjects: 0
Study 31116739 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative learning with metacognitive prompts
Number of subjects: 171
Study 31116739 — intervention group
Group type: COMPARATOR
Intervention: Collaborative learning without metacognitive prompts
Number of subjects: 171
Study 31116739 — intervention group
Group type: COMPARATOR
Intervention: Individual learning with metacognitive prompts
Number of subjects: 171
Study 31116739 — intervention group
Group type: COMPARATOR
Intervention: Individual learning without metacognitive prompts
Number of subjects: 171
Study 27778643 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% caloric restriction (CR) for 12 months
Number of subjects: 51
Study 27778643 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum (control) diet for 12 months
Number of subjects: 51
Study 26195058 — intervention group
Group type: EXPERIMENTAL
Intervention: GA40 (40 mg/mL three-times weekly)
Number of subjects: 209
Study 26195058 — intervention group
Group type: COMPARATOR
Intervention: GA20 (20 mg/mL daily)
Number of subjects: 209
Study 23877462 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral augmentation procedures with advanced imaging (MRI, CT, or bone scan)
Number of subjects: 409
Study 23877462 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral augmentation procedures with Workers compensation
Number of subjects: 409
Study 21904088 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS extended release (MAS XR)
Number of subjects: 62
Study 21904088 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS immediate release (MAS IR)
Number of subjects: 62
Study 21904088 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS IR and MAS XR
Number of subjects: 62
Study 19121433 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs)
Number of subjects: 5745
Study 19121433 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 5745
Study 16940098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid
Number of subjects: 114
Study 16940098 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 114
Study 15078379 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg.kg(‐1) rocuronium bromide
Number of subjects: 61
Study 15078379 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg.kg(‐1) rocuronium bromide
Number of subjects: 61
Study 10903790 — intervention group
Group type: EXPERIMENTAL
Intervention: O + M + L
Number of subjects: 135
Study 10903790 — intervention group
Group type: COMPARATOR
Intervention: O + M
Number of subjects: 135
Study 9285652 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg/day diltiazem (morning dosing)
Number of subjects: 68
Study 9285652 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg/day diltiazem (evening dosing)
Number of subjects: 68
Study 8324395 — intervention group
Group type: EXPERIMENTAL
Intervention: Seldane-D (terfenadine 60 mg + pseudo-ephedrine 120 mg)
Number of subjects: 14
Study 8324395 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 14
Study 8324395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudo-ephedrine (120 mg)
Number of subjects: 14
Study 8324395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3574053 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling for 1 hour at 60% VO2max
Number of subjects: 10
Study 3574053 — intervention group
Group type: EXPERIMENTAL
Intervention: Running for 1 hour at 60% VO2max
Number of subjects: 10
Study 3574053 — intervention group
Group type: COMPARATOR
Intervention: Control sessions (5 subjects)
Number of subjects: 10
Study 31693129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid
Number of subjects: 6097
Study 31693129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate
Number of subjects: 6097
Study 31693129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate
Number of subjects: 6097
Study 31330502 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension Training (ST)
Number of subjects: 57
Study 31330502 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Resistance Training (RT)
Number of subjects: 57
Study 31330502 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 57
Study 27457511 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (maximum 2.5 or 1.5 mg three times daily)
Number of subjects: 0
Study 27457511 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (maximum 2.5 mg three times daily)
Number of subjects: 0
Study 27457511 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0
Study 27457511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25980735 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-minute interval between tumescent anesthetic solution infiltration and start of surgery
Number of subjects: 75
Study 25980735 — intervention group
Group type: COMPARATOR
Intervention: 15-minute interval between tumescent anesthetic solution infiltration and start of surgery
Number of subjects: 75
Study 25980735 — intervention group
Group type: COMPARATOR
Intervention: 10-minute interval between tumescent anesthetic solution infiltration and start of surgery
Number of subjects: 75
Study 23205588 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 69
Study 23205588 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 69
Study 21813223 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at predicted effect site concentrations of 0.4, 0.8, 1.2, 1.6, and 2.0 μg/mL
Number of subjects: 20
Study 21813223 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at predicted effect site concentrations of 1.6 and 2.0 μg/mL
Number of subjects: 20
Study 21813223 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at predicted effect site concentration of 2.0 μg/mL
Number of subjects: 20
Study 21813223 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at predicted effect site concentration of 1.2 μg/mL or less
Number of subjects: 20
Study 21813223 — intervention group
Group type: COMPARATOR
Intervention: Propofol group
Number of subjects: 20
Study 19231302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with intravenous midazolam and placebo throat spray (midazolam group)
Number of subjects: 213
Study 19231302 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo sedation and pharyngeal anaesthesia with lidocaine (lidocaine group)
Number of subjects: 213
Study 19231302 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo sedation and placebo throat spray (placebo group)
Number of subjects: 213
Study 19231302 — intervention group
Group type: COMPARATOR
Intervention: No intravenous cannula nor throat spray (control group)
Number of subjects: 213
Study 16698410 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (250 mg, and an additional 250 mg if necessary)
Number of subjects: 971
Study 16698410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 971
Study 16698410 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline and Placebo
Number of subjects: 971
Study 15321793 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 kcal/d diet with 4 servings/d of liquid meal replacement (MR)
Number of subjects: 123
Study 15321793 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200-1500 kcal/d balanced deficit diet (BDD)
Number of subjects: 123
Study 15321793 — intervention group
Group type: COMPARATOR
Intervention: Nondieting (ND) approach
Number of subjects: 123
Study 15321793 — intervention group
Group type: EXPERIMENTAL
Intervention: MR and BDD
Number of subjects: 123
Study 15321793 — intervention group
Group type: EXPERIMENTAL
Intervention: MR
Number of subjects: 123
Study 15321793 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 123
Study 11798062 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly allocated interventions in controlled clinical trials
Number of subjects: 0
Study 11798062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective, subgroup specific endpoint selection
Number of subjects: 0
Study 11798062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective, subgroup specific endpoint event rates
Number of subjects: 0
Study 11798062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective, subgroup specific therapy efficacy
Number of subjects: 0
Study 11798062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective, subgroup specific nonuniform type I error levels
Number of subjects: 0
Study 9669257 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 36
Study 9669257 — intervention group
Group type: COMPARATOR
Intervention: Control (no L-arginine)
Number of subjects: 36
Study 8077575 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula with 2.91 g protein/100 kcal (IS)
Number of subjects: 64
Study 8077575 — intervention group
Group type: COMPARATOR
Intervention: Soy-based formula with 2.45 g protein/100 kcal (EF)
Number of subjects: 64
Study 2758453 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg diltiazem
Number of subjects: 31
Study 2758453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 364781 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic inactivation (neutral red 1% solution + 15-min exposure to 40 watt light of 440-550 nm)
Number of subjects: 21
Study 364781 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbolization
Number of subjects: 21
Study 364781 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxuridine (IDU) ointment
Number of subjects: 21
Study 29373661 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy
Number of subjects: 168
Study 29373661 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 168
Study 28851784 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (50 µg daily from early pregnancy until 6 months postpartum)
Number of subjects: 800
Study 28851784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily from early pregnancy until 6 months postpartum)
Number of subjects: 800
Study 26592377 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-unit PRBC transfusion
Number of subjects: 230
Study 26592377 — intervention group
Group type: COMPARATOR
Intervention: Double-unit PRBC transfusion
Number of subjects: 230
Study 24286136 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab (50 mg, 140 mg, or 210 mg subcutaneously every two weeks for 6 doses; or 420 mg or 700 mg intravenously every 4 weeks for two doses)
Number of subjects: 40
Study 24286136 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 40
Study 24286136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21062790 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol‐remifentanil
Number of subjects: 60
Study 21062790 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia (BAL) with fentanyl‐nitrous oxide‐sevoflurane
Number of subjects: 60
Study 18467185 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon alfa-2b 1500 microg every 4 weeks with oral ribavirin 800 mg/day for 24 weeks
Number of subjects: 43
Study 18467185 — intervention group
Group type: COMPARATOR
Intervention: Albinterferon alfa-2b 1500 microg every 2 weeks with oral ribavirin 800 mg/day for 24 weeks
Number of subjects: 43
Study 17096501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) injection
Number of subjects: 0
Study 14648885 — intervention group
Group type: EXPERIMENTAL
Intervention: High-field (3.0 T) magnetic resonance (MR) system
Number of subjects: 16
Study 10853700 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation training for 7 weeks (5 series of 6 6-s isometric actions at 60 to 70% of maximal isometric voluntary action)
Number of subjects: 9
Study 10853700 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation training for 7 weeks
Number of subjects: 9
Study 9357405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 138
Study 9357405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 8375243 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (10 g)
Number of subjects: 0
Study 8375243 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (20 g)
Number of subjects: 0
Study 8375243 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous glucagon (1.0 mg)
Number of subjects: 0
Study 8375243 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Ala (40 g)
Number of subjects: 0
Study 8375243 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (5.0 mg)
Number of subjects: 0
Study 8375243 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (0.25 mg)
Number of subjects: 0
Study 8375243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3514202 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA Low Birth Weight
Number of subjects: 85
Study 3514202 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematalac
Number of subjects: 85
Study 3514202 — intervention group
Group type: EXPERIMENTAL
Intervention: Preaptamil
Number of subjects: 85
Study 3514202 — intervention group
Group type: COMPARATOR
Intervention: Expressed Breast Milk (EBM)
Number of subjects: 85
Study 31394948 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM cannula
Number of subjects: 126
Study 29480440 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly short-term lotteries for 13 weeks
Number of subjects: 0
Study 29480440 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term lotteries in combination with an additional long-term lottery after 26 weeks
Number of subjects: 0
Study 29480440 — intervention group
Group type: COMPARATOR
Intervention: Control arm without lottery-deadlines
Number of subjects: 0
Study 29480440 — intervention group
Group type: COMPARATOR
Intervention: All arms (including control)
Number of subjects: 0
Study 27019158 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg single dose after high-fat breakfast
Number of subjects: 15
Study 27019158 — intervention group
Group type: COMPARATOR
Intervention: Faldaprevir 240 mg single dose in fasting state
Number of subjects: 15
Study 27019158 — intervention group
Group type: COMPARATOR
Intervention: Faldaprevir 240 mg single dose with omeprazole 40 mg q.d. for 5 days
Number of subjects: 15
Study 24885833 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid‐based formula (AAF) for 80 days starting at SD5 (CD-C)
Number of subjects: 46
Study 24885833 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid‐based formula (AAF) for 80 days starting at SD5 (CD-I)
Number of subjects: 46
Study 24204067 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnerships for Health QI program
Number of subjects: 998
Study 21921426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg preoperative dose
Number of subjects: 60
Study 21921426 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 60
Study 18640826 — intervention group
Group type: EXPERIMENTAL
Intervention: MF‐DPI 400 microg QD in the morning
Number of subjects: 1537
Study 18640826 — intervention group
Group type: EXPERIMENTAL
Intervention: MF‐DPI 400 microg QD in the evening
Number of subjects: 1537
Study 18640826 — intervention group
Group type: COMPARATOR
Intervention: MF‐DPI 400 microg QD in the morning and evening
Number of subjects: 1537
Study 16612448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice a day for one week
Number of subjects: 24
Study 16612448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12531630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg CS6 in PLG microspheres with buffer
Number of subjects: 5
Study 12531630 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg CS6 in PLG microspheres with buffer
Number of subjects: 5
Study 12531630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg CS6 as free protein in saline
Number of subjects: 5
Study 12531630 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg CS6 as free protein in saline
Number of subjects: 5
Study 12531630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg CS6 in PLG microspheres with rice-based buffer
Number of subjects: 5
Study 12531630 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg CS6 in PLG microspheres with rice-based buffer
Number of subjects: 5
Study 12531630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg CS6 as free protein in rice-based buffer
Number of subjects: 5
Study 12531630 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg CS6 as free protein in rice-based buffer
Number of subjects: 5
Study 10951629 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic glutathione (GSH) - continuous infusion of 600g daily for 30 days
Number of subjects: 110
Study 10951629 — intervention group
Group type: COMPARATOR
Intervention: TAD - same dosage, course and route as GSH
Number of subjects: 110
Study 8831579 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreoscan scintigraphy
Number of subjects: 21
Study 8831579 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging techniques
Number of subjects: 21
Study 8831579 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of conventional techniques and Octreoscan scintigraphy
Number of subjects: 21
Study 8831579 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic ultrasonography
Number of subjects: 21
Study 1426513 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodostearic acid pessaries in polyethylene glycol (PEG) base
Number of subjects: 0
Study 1426513 — intervention group
Group type: COMPARATOR
Intervention: PEG base pessaries
Number of subjects: 0
Study 2883063 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary intensive care units (CCU) with higher hospitalization/year and more sophisticated instrumental equipment
Number of subjects: 20020
Study 2883063 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients hospitalized within the first few hours from symptom onset
Number of subjects: 20020
Study 2883063 — intervention group
Group type: COMPARATOR
Intervention: Patients hospitalized after 12 hours
Number of subjects: 20020
Study 31745744 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR)
Number of subjects: 176
Study 31745744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)
Number of subjects: 176
Study 31745744 — intervention group
Group type: COMPARATOR
Intervention: Myocardial perfusion scintigraphy (MPS) or cardiovascular magnetic resonance (CMR)
Number of subjects: 176
Study 29045582 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall injury prevention strategy (comanagement model with nurse Falls Care Manager)
Number of subjects: 5451
Study 29045582 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (evidence-based information on falls prevention)
Number of subjects: 5451